>

Shmuel Rubinstein - CLAL BIOTECHNOLOGY External Director

<div class='circular--portrait' style='background:#FF9E01;color: white;font-size:3em;padding-top: 40px;;'>CLA</div>
  Director
Mr. Shmuel Rubinstein serves as External Director at Clal Biotechnology Industries Ltd. since February 17, 2011. He also serves Tero Pharma Industries Ltd. since 1990.
Age: 78  Director Since 2011      
972 3 612 1616  http://www.cbi.co.il

Management Efficiency

The company has return on total asset (ROA) of (5.15) % which means that it has lost $5.15 on every $100 spent on asset. This is way below average. Similarly, it shows return on equity (ROE) of (1.79) % meaning that it generated substantial loss on money invested by shareholders.
The company has accumulated 52.28 M in total debt with debt to equity ratio (D/E) of 6.3 indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. CLAL BIOTECHNOLOGY has Current Ratio of 3.6 suggesting that it is liquid and has the ability to pay its financial obligations in time and when they become due.

Similar Executives

Showing few of many executives

DIRECTOR Since

Miriam HaranICL ISRAEL CHEM
2009
Avisar PazICL ISRAEL CHEM
2001
Aviad KaufmanICL ISRAEL CHEM
2014
Reem AminoachICL ISRAEL CHEM
2017
Ovadia EliICL ISRAEL CHEM
2011
Yoav DoppeltICL ISRAEL CHEM
2018
Ruth RalbagICL ISRAEL CHEM
2018
Ron MoskovitzICL ISRAEL CHEM
2016
Shimon EckhausICL ISRAEL CHEM
2015
Yaacov DiorICL ISRAEL CHEM
2011
Lior ReitblattICL ISRAEL CHEM
2017
Eran SarigICL ISRAEL CHEM
2010
Nadav KaplanICL ISRAEL CHEM
2018
Geoffery MerszeiICL ISRAEL CHEM
2015
Sagi KablaICL ISRAEL CHEM
2016

Company Summary

Clal Biotechnology Industries Ltd. is a private equity and venture capital firm specializing in development stage, pre-clinical incubation, seed, start-up, early venture, emerging growth, mid venture, late venture, PIPEs, and growth capital stages of financing. It operates as a subsidiary of Clal Industries and Investments Ltd. CLAL BIOTECHNOLOGY operates under Biotechnology classification in Israel and is traded on Tel Aviv Stock Exchange.CLAL BIOTECHNOLOGY (CBI) is traded on Tel Aviv Stock Exchange in Israel and employs 14 people.

CLAL BIOTECHNOLOGY Leadership Team

Ofer Goldberg, VPView
Sigalia Heifetz, DirectorView
Shmuel Rubinstein, External DirectorView
Tomer Babai, DirectorView
Dafna Gruber, DirectorView
Aharon Schwartz, DirectorView
Gavriel Barabash, DirectorView
Isaac Kohlberg, DirectorView
Nofar Malovani, DirectorView
Assaf Segal, CFOView
Ofer Gonen, Vice PresidentView
Avraham Fischer, Chairman of the BoardView
Yuval Yanai, External DirectorView
Julian Adams, President Chief Scientific OfficerView
Orit Lidor, VP and General CounselView

Stock Performance Indicators

Current Sentiment - CBI

CLAL BIOTECHNOLOGY Investor Sentiment

Most of Macroaxis users are currently bullish on CLAL BIOTECHNOLOGY. What is your opinion about investing in CLAL BIOTECHNOLOGY? Are you bullish or bearish?
Bullish
Bearish
98% Bullish
2% Bearish
Skip

CLAL BIOTECHNOLOGY Pair Correlation

Equities Pair Trading Analysis

Correlation analysis and pair trading evaluation for W W and DXP Enterprises. Pair trading can be used as a hedging technique within a particular sector or industry or even over random equities to generate better risk-adjusted return
Run Pair Correlation  
Check out Trending Equities. Please also try Analyst Recommendations module to analyst recommendations and target price estimates broken down by several categories.